Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: The M. D. Anderson Cancer Center experience

Leukemia and Lymphoma

Volumn 51, Issue 7, 2010, Pages 1217-1224

  Mazloom, Ali ^a   Fowler, Nathan ^b   Medeiros, L Jeffrey ^b   Iyengar, Puneeth ^c   Horace, Patrecia ^c   Dabaja, Bouthaina S ^c  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

diffuse large B cell lymphoma; prognostic factors; rituximab; Testis

Indexed keywords

BETA 2 MICROGLOBULIN; BLEOMYCIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; HYDROCORTISONE; IFOSFAMIDE; LACTATE DEHYDROGENASE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PACLITAXEL; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; AXILLARY LYMPH NODE; BONE MARROW; BRAIN; CANCER CENTER; CANCER RADIOTHERAPY; CANCER STAGING; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG MEGADOSE; FOLLOW UP; HUMAN; IMMUNOPHENOTYPING; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LEPTOMENINX; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEEDLE BIOPSY; ORCHIECTOMY; OVERALL SURVIVAL; PARENCHYMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SALVAGE THERAPY; SOFT TISSUE; TESTIS; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR RECURRENCE; TUMOR REGRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; L-LACTATE DEHYDROGENASE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 77954098211     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428191003793358     Document Type: Article

References (36)

1. Buskirk SJ, Evans RG, Banks PM, O'Connell MJ, Earle JD. Primary lymphoma of the testis. Int J Radiat Oncol Biol Phys 1982;8:1699-1703.
2. Sussman EB, Hajdu SI, Lieberman PH, Whitmore WF. Malignant lymphoma of the testis: a clinicopathologic study of 37 cases. J Urol 1977;118:1004-1007.
3. Read G. Lymphomas of the testis - results of treatment 1960-1977. Clin Radiol 1981;32:687-692.
4. Zucca E, Roggero E, Bertoni F, Cavalli F. Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol 1997;8:727-737.
5. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 1972;29:252-260.
6. Otter R, Gerrits WB, vd Sandt MM, Hermans J, Willemze R. Primary extranodal and nodal non-Hodgkin's lymphoma. A survey of a population-based registry. Eur J Cancer Clin Oncol 1989;25:1203-1210. (Pubitemid 19209616)
7. Moller MB, d'Amore F, Christensen BE. Testicular lymphoma: a population-based study of incidence, clinicopathological correlations and prognosis. The Danish Lymphoma Study Group, LYFO. Eur J Cancer 1994;30A:1760-1764.
8. Tweed CS, Peck RJ. A sonographic appearance of testicular lymphoma. Clin Radiol 1991;43:341-342.
9. Verma N, Lazarchick J, Gudena V, Turner J, Chaudhary UB. Testicular lymphoma: an update for clinicians. Am J Med Sci 2008;336:336-341.
10. Zucca E, Conconi A, Mughal TI, et al. . Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003;21:20-27.
11. Salem YH, Miller HC. Lymphoma of genitourinary tract. J Urol 1994;151:1162-1170.
12. Ferry JA, Harris NL, Young RH, Coen J, Zietman A, Scully RE. Malignant lymphoma of the testis, epididymis, and spermatic cord. A clinicopathologic study of 69 cases with immunophenotypic analysis. Am J Surg Pathol 1994;18:376-390.
13. Al-Abbadi MA, Hattab EM, Tarawneh MS, Amr SS, Orazi A, Ulbright TM. Primary testicular diffuse large B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup: a study of 18 cases. Mod Pathol 2006;19:1521-1527.
14. Miedler JD, MacLennan GT. Primary testicular lymphoma. J Urol 2007;178:2645.
15. Vural F, Cagirgan S, Saydam G, Hekimgil M, Soyer NA, Tombuloglu M. Primary testicular lymphoma. J Natl Med Assoc 2007;99:1277-1282.
16. Shahab N, Doll DC. Testicular lymphoma. Semin Oncol 1999;26:259-269.
17. Pectasides D, Economopoulos T, Kouvatseas G, et al. Anthracycline-based chemotherapy of primary non-Hodgkin's lymphoma of the testis: the Hellenic Cooperative Oncology Group experience. Oncology 2000;58:286-292.
18. Fonseca R, Habermann TM, Colgan JP, et al. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer 2000;88:154-161. (Pubitemid 30027691)
19. Crellin AM, Hudson BV, Bennett MH, Harland S, Hudson GV. Non-Hodgkin's lymphoma of the testis. Radiother Oncol 1993;27:99-106.
20. Ciatto S, Cionini L. Malignant lymphoma of the testis. Acta Radiol Oncol Radiat Phys Biol 1979;18:572-576.
21. Doll DC, Weiss RB. Malignant lymphoma of the testis. Am J Med 1986;81:515-524.
22. Visco C, Medeiros LJ, Mesina OM, et al. Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicinbased therapy? Clin Lymphoma 2001;2:40-46.
23. Duncan PR, Checa F, Gowing NF, McElwain TJ, Peckham MJ. Extranodal non-Hodgkin's lymphoma presenting in the testicle: a clinical and pathologic study of 24 cases. Cancer 1980;45:1578-1584.
24. Touroutoglou N, Dimopoulos MA, Younes A, et al. Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy. J Clin Oncol 1995;13:1361-1367.
25. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982;49:2112-2135.
26. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
27. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
28. Carbone PP, Kaplan HS,Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1861.
29. Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
30. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
31. Cox D. Regression models in life tables. J R Stat Soc 1972;B34:187-220.
32. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
33. Horstmann WG, Timens W. Lack of adhesion molecules in testicular diffuse centroblastic and immunoblastic B cell lymphomas as a contributory factor in malignant behaviour. Virchows Arch 1996;429:83-90.
34. Riemersma SA, Jordanova ES, Schop RF, et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 2000;96:3569-3577.
35. Haioun C, Besson C, Lepage E, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 2000;11:685-690.
36. Aviles A, Nambo MJ, Cleto S, Neri N, Huerta-Guzman J. Rituximab and dose-dense chemotherapy in primary testicular lymphoma. Clin Lymphoma Myeloma 2009;9:386-389.